Michael Berger on tumour profiling to identify therapeutic biomarkers and guide clinical care in cancer #EMBLCanGen

Happy to share our first bioRxiv on how oncologic therapy shapes the fitness landscape of clonal hematopoiesis in cancer patients. Fantastic team effort between Kelly Bolton MD PhD, Ryan N. Ptashkin, @tgao2018 and Elli Papaemmanuil, PhD with support from many others! bit.ly/34acSJL

Come visit our OncoKB™ poster (#2148) about annotation of the oncogenic effect and diagnostic, prognostic, and therapeutic implications of somatic genomic variants in hematologic malignancies #ASH2019 @sloan_kettering Ritika Kundra Hongxin Zhang Debyani Chakravarty, PhD 🇺🇦

The head of the United States Food and Drug Administration (!) Dr. Stephen M. Hahn does not understand the difference between relative and absolute risk reduction -- a basic, fundamental concept in medicine, statistics and clinical trial interpretation. It just gets worse and worse.😢

It's Friday and it's time for a new preprint biorxiv.org/content/10.110… : MSI status for cancer pts is critical as it is the first tissue-agnostic biomarker for treatment with pembrolizumab. We've been using NGS data from #MSKimpact + MSISensor to detect MSI status but 🧵 (1/n)

Now online in Cancer Discovery: Cancer Causative Mutations Occurring in Early #Embryogenesis by Fresia Pareja Ryan N. Ptashkin David Brown, Jorge Reis-Filho, Diana Mandelker and colleagues MSK Department of Pathology & Laboratory Medicine @sloan_kettering cancerdiscovery.aacrjournals.org/content/early/…

This month's cover of Cancer Discovery features work on mosaic variants in cancer susceptibility genes by Fresia Pareja Ryan N. Ptashkin David Brown, Jorge Reis-Filho, Diana Mandelker and colleagues MSK Department of Pathology & Laboratory Medicine @sloan_kettering cancerdiscovery.aacrjournals.org/content/early/…

🔥Extra-hot pre-print before this hellsite goes up in smoke 🔥 New horizons open up when sequencing costs go ↘️ Ultima Genomics Interested in deep cfDNA WGS for ultra-sensitive cancer detection? Duplex sequencing at genome scale? biorxiv.org/content/10.110… Check out 🪡👇

Thrilled to be attending #AACR2023 in Orlando! 😃 We're proud to present 3 posters and share how C2i Genomics technology is making a real difference in MRD testing for cancer patients. I'd love to meet you over coffee at booth 1161 and chat more about it! ☕️ #MRD #WGS

By now, i’m sure most of you saw that FDA is planning to regulate LDTs (public-inspection.federalregister.gov/2023-21662.pdf). A paper, suggesting clinical labs failed PT testing, is cited in the FDA doc as one of the reasons. What if the analyses in this paper were flawed? 🧵👇🏼 doi.org/10.5858/arpa.2…

Recently published #CancerResearch: Ahmet Zehir Ryan N. Ptashkin MArcila MSK Department of Pathology & Laboratory Medicine develop and test the #mskimpact Heme sequencing panel and platform to profile #BloodCancers in the clinic Cancer at Nature Portfolio nature.com/articles/s4146…